News | September 23, 2024
AstraZeneca Pharma India to launch Tremelimumab
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
The approval further adds to Biocon’s portfolio of complex drug products
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome
Subscribe To Our Newsletter & Stay Updated
